A phase I clinical trial currently investigates GPRC5D-directed CAR-T cell therapy (MCARH109) in relapsed/refractory multiple myeloma, including patients who have received prior BCMA-targeted therapies (NCT04555551). This evidence concerns the gene TNFRSF17 and AL amyloidosis.